Company intelligence / Profile preview

LightOx

Newcastle upon Tyne, England, United Kingdomlightox.co.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

LightOx has developed a new class of light activated small molecule therapeutics designed to selectively target and kill cancer cells upon exposure to light. Their lead candidates are formulated for topical treatment of oral cancers. The company’s approach allows minimal off-target toxicity and the potential for joint diagnostic-treatment agents. Lead programs are preclinical; no clinical results have been published yet.

Therapeutic areas: OncologyInfectious DiseasesRheumatology
Modalities: Small moleculesAntibody-drug conjugates (ADCs)Fluorescent probes/drug-like compoundsHDAC inhibitor fusions
Industry: Biotech

Drug pipeline

1 asset

LXD191

Preclinical

Partnerships

Merck – distribution deal for research tools under Research Use Only model.

Beyond the preview

Go deeper on LightOx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LightOx.

Explore the full profile